Teva's Turnaround: From Losses to Profits, Stock Soars Over 100% in a Year
Teva Pharmaceutical Industries has staged a dramatic financial recovery, posting a $1.4 billion net profit for 2025 and igniting a massive rally in its share price. Investors are now weighing whether the generic drug giant's remarkable comeback has further to run.